Overview

Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients

Status:
Unknown status

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

To evaluate efficacy and safety of Ombitasvir, paritaprevir, and ritonavir plus ribavirin based therapy for chronic hepatitis C with or without compensated cirrhosis in haemodialysis patients.

Phase:

Phase 2

Details

Lead Sponsor:

Ain Shams University

Treatments:

Ribavirin
Ritonavir